Scientists hunt for clues to predict lung cancer drug success
NCT ID NCT04312308
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to find immune-related biomarkers that could predict how well patients with non-small cell lung cancer respond to the drug atezolizumab. Researchers analyzed blood and tumor samples from 100 participants to track immune cell changes and genetic markers. The goal was to improve treatment decisions by identifying early signs of response or resistance.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Yonsei Severance Hospital
Seoul, South Korea